£4.3M
The seed round was co-led by Boehringer Ingelheim Venture Fund and Scottish Enterprise to support laboratory establishment and team expansion.
GT
Glox Therapeutics
Glox Therapeutics develops precision antibiotic therapies to combat antimicrobial resistance.
£4.3MTotal raised
Glox Therapeutics develops precision antibiotic therapies using naturally occurring bacteriocins to target antimicrobial-resistant pathogens. The company emerged as a spin-out from the Universities of Glasgow and Oxford.
Filed accounts
Cash at bank
Members only
Net current assets
Members only
Total assets less current liabilities
Members only
Net assets
Members only
Shareholders' funds
Members only
Fixed assets
Members only
Cash, assets and headcount from Glox Therapeutics's latest Companies House filing — with year-on-year movement, free with a Winfred account.
Categories
Founders
Daniel Walker
Professor
Daniel serves as chief scientific officer at Glox Therapeutics and professor of microbiology at the University of Strathclyde. He previously held professorial and research roles at the University of Glasgow.
LinkedInCK
Colin Kleanthous
Professor